LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)
NCT ID: NCT05677308
Last Updated: 2025-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
61 participants
OBSERVATIONAL
2023-03-07
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lynparza Breast Cancer Clinical Experience Investigation
NCT03590938
Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer
NCT00491816
Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer
NCT02562118
LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer
NCT04032080
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
NCT07281976
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This investigation will be conducted for application for re-examination specified in Article 14-4 of the Pharmaceutical Affairs Law.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Toshimitsu Tokimoto
Role: STUDY_DIRECTOR
AstraZeneca KK
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Aichi, , Japan
Research Site
Akita, , Japan
Research Site
Aomori, , Japan
Research Site
Chiba, , Japan
Research Site
Ehime, , Japan
Research Site
Fukui, , Japan
Research Site
Fukuoka, , Japan
Research Site
Gifu, , Japan
Research Site
Gunma, , Japan
Research Site
Hiroshima, , Japan
Research Site
Hokkaido, , Japan
Research Site
Hyōgo, , Japan
Research Site
Ibaraki, , Japan
Research Site
Ishikawa, , Japan
Research Site
Kanagawa, , Japan
Research Site
Kochi, , Japan
Research Site
Kumamoto, , Japan
Research Site
Kyoto, , Japan
Research Site
Mie, , Japan
Research Site
Miyagi, , Japan
Research Site
Nara, , Japan
Research Site
Niigata, , Japan
Research Site
Numakunai, , Japan
Research Site
Okayama, , Japan
Research Site
Okinawa, , Japan
Research Site
Osaka, , Japan
Research Site
Ōita, , Japan
Research Site
Saga, , Japan
Research Site
Saitama, , Japan
Research Site
Shiga, , Japan
Research Site
Shimane, , Japan
Research Site
Shizuoka, , Japan
Research Site
Tochigi, , Japan
Research Site
Tokyo, , Japan
Research Site
Tottori, , Japan
Research Site
Toyama, , Japan
Research Site
Wakayama, , Japan
Research Site
Yamaguchi, , Japan
Research Site
Yamanashi, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D081CC00012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.